RoboCT Raises $13.7M for Exoskeleton Robotics Growth

RoboCT, a pioneer in advanced exoskeleton robotics, has successfully closed a RMB 100 million (approximately $13.7 million USD) Series A+ funding round. This significant capital infusion is earmarked to propel the company's ambitious growth plans, including enhancing its product development pipeline, broadening its international market footprint, and bolstering its operational infrastructure within the rapidly expanding field of assistive robotics.

The Hangzhou-based firm has established a strong reputation for its innovative rehabilitation and elderly care exoskeleton solutions. Notably, RoboCT was the first entity in China to achieve NMPA registration for lower-limb exoskeletons designed to address central nervous system disorders, underscoring its leadership in medical robotics. Since its inception in 2017, RoboCT has cultivated a robust ecosystem encompassing proprietary core components, a diverse product range, and intelligent control systems.

Central to RoboCT's offering is the UGO exoskeleton robot, a device that has seen widespread adoption across China, deployed in over 200 hospitals and more than 1,000 healthcare institutions. This technology leverages sophisticated intention detection and multi-sensor data fusion to aid individuals recovering from spinal cord injuries, strokes, and other conditions causing muscle weakness. The company's operational scale is substantial, having manufactured over 100,000 units and facilitated more than 910,000 patient therapy sessions through its Robot as a Service (RaaS) model.

In a strategic pivot, RoboCT recently made its debut at CES 2026, showcasing its new GoGo Exoskeleton series. This move signals a deliberate expansion beyond purely medical applications into consumer-oriented mobility enhancement solutions for daily life, targeting a wider demographic seeking improved personal mobility and independence. This diversification is a key element of the company's evolving market strategy.

The Series A+ financing was spearheaded by Fortune Capital, with significant participation from follow-on investors including Essence Securities, Poly Capital, and existing supporter Blue Run Ventures China (BRV China). The influx of capital will be instrumental in refining operational efficiencies, accelerating the commercialization of its expanded product lines, and supporting its push into new global territories. RoboCT's influence also extends to industry development, as it has contributed to drafting standards for medical lower-limb exoskeleton robots.

The exoskeleton market is experiencing considerable growth, driven by an aging global population, increasing awareness of rehabilitation technologies, and advancements in AI and robotics. The medical and assistive robotics sector is projected to reach tens of billions of dollars in the coming years, with companies like RoboCT well-positioned to capture a significant share by offering integrated hardware, software, and service models. RoboCT's dual focus on clinical rehabilitation and consumer mobility positions it uniquely within this dynamic market.